TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) has issued an announcement.
Mochida Pharmaceutical Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a 2.2% increase in net sales to ¥105,159 million. The company achieved significant growth in operating profit, which rose by 40.1% to ¥8,126 million, and ordinary profit, which increased by 33.6% to ¥8,067 million. Despite a decrease in comprehensive income, the company maintained stable dividend payments and improved its financial position with a higher equity-to-asset ratio.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and sale of pharmaceutical products. The company is listed on the Tokyo Stock Exchange and is known for its contributions to healthcare through innovative drug development.
YTD Price Performance: -11.03%
Average Trading Volume: 26,864
Technical Sentiment Signal: Sell
Current Market Cap: Yen105.3B
See more data about 4534 stock on TipRanks’ Stock Analysis page.